関連する実験動画
Updated: Jan 29, 2026

09:36
RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
Published on: April 10, 2018
26.3K
設計された非コーディングRNAの小分子阻害剤は,HER2陰性がんをヘルセプチンに敏感にする
Matthew G Costales1, Dominic G Hoch1, Daniel Abegg1
1Department of Chemistry , The Scripps Research Institute , 130 Scripps Way , Jupiter , Florida 33458 , United States.
Journal of the American Chemical Society
|February 7, 2019
まとめ
新種の小分子は選択的にmiR- 515を標的にしてスフィンゴシンキナーゼ1 (SK1) とスフィンゴシン1- リン酸 (S1P) のレベルを上昇させ,HER2- がん細胞をHerceptinのような抗HER2療法に敏感にします.
科学分野:
- 生物化学
- 分子生物学
- 癌 研究
背景:
- マイクロRNA (miRNA) の不調は癌に関与している.
- スフィンゴシンキナーゼ1 (SK1) とスフィンゴシン1- リン酸 (S1P) 経路の変化は,がんの進行と薬剤耐性に関連しています.
- HER2 ネガティブ (HER2-) がんでは,ヘルセプトンなどのHER2- 標的治療に敏感性が欠けていることが多い.
研究 の 目的:
- 特定のmiRNA前駆体を 選択的に標的とする小分子を設計する.
- この分子がSK1/S1P経路と癌細胞の表型に及ぼす影響を調査する.
- この分子がHER2 がん細胞を既存の標的治療に敏感にするかどうかを判断する.
主な方法:
- miR-515ヘアピン前駆体を標的とした二次元小分子 (2) の設計と合成.
- SK1とS1Pレベル,細胞移動,タンパク質発現を評価するための細胞ベースの測定法.
- ターゲットプロファイリングとオフターゲット効果の評価のためのChem-CLIPとRNA-seq.
- 様々ながん細胞系における抗HER2療法 (ハーセプチン) への感受性の評価
主要な成果:
- 小分子 (2) は選択的にmiR- 515の生成を抑制し,SK1とS1Pのレベルを上昇させ,細胞の移動を強めた.
- 標的プロファイリングは miR-515 ヘアピン前駆体への化合物の選択的結合を確認した.
- MCF-7細胞におけるERBB2/HER2を含むがん関連タンパク質をアップレギュレーションした化合物.
- HER2 乳がん,肝細胞がん,トリプルネガティブ乳がん細胞を Herceptin に適用する.
- miR- 515の発現が欠如した正常な乳頭上皮細胞は,化合物2の影響を受けなかった.
結論:
- 新しい小分子は miR-515を選択的に標的にし,SK1/S1P経路を調節する.
- このアプローチは HER2 がん細胞を HER2 標的治療に効果的に敏感にし,潜在的な精密医療戦略を提供します.
- この発見は,これまで無感であったがんに対する 既存の標的がん薬の治療的有用性を拡大する方法を示唆しています.
関連する概念動画
Negative Regulator Molecules
38.5K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.5K
lncRNA - Long Non-coding RNAs
9.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.9K
RNA Splicing
60.6K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.6K
RNA Stability
35.7K
Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
35.7K
Transfer RNA Synthesis
13.3K
One of the unique features of tRNA is the presence of modified bases. In some tRNAs, modified bases account for nearly 20% of the total bases in the molecule. Altogether, these unusual bases protect the tRNA from enzymatic degradation by RNases.
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
13.3K
Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K

